Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
RAD's Cash to Debt is ranked lower than
54% of the 495 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.66 vs. RAD: 0.03 )
RAD' s 10-Year Cash to Debt Range
Min: 0   Max: 0.13
Current: 0.03

0
0.13
Equity to Asset -0.30
RAD's Equity to Asset is ranked lower than
56% of the 494 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.44 vs. RAD: -0.30 )
RAD' s 10-Year Equity to Asset Range
Min: -0.38   Max: 0.47
Current: -0.3

-0.38
0.47
Interest Coverage 1.70
RAD's Interest Coverage is ranked lower than
54% of the 319 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.77 vs. RAD: 1.70 )
RAD' s 10-Year Interest Coverage Range
Min: 0.02   Max: 4.75
Current: 1.7

0.02
4.75
F-Score: 5
Z-Score: 2.87
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 2.83
RAD's Operating margin (%) is ranked higher than
68% of the 440 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. RAD: 2.83 )
RAD' s 10-Year Operating margin (%) Range
Min: -8.84   Max: 6.03
Current: 2.83

-8.84
6.03
Net-margin (%) 0.98
RAD's Net-margin (%) is ranked higher than
62% of the 440 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.36 vs. RAD: 0.98 )
RAD' s 10-Year Net-margin (%) Range
Min: -11.09   Max: 7.37
Current: 0.98

-11.09
7.37
ROA (%) 3.59
RAD's ROA (%) is ranked higher than
71% of the 441 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.50 vs. RAD: 3.59 )
RAD' s 10-Year ROA (%) Range
Min: -35.01   Max: 18.22
Current: 3.59

-35.01
18.22
ROC (Joel Greenblatt) (%) 19.83
RAD's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 440 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.83 vs. RAD: 19.83 )
RAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -45.25   Max: 19.83
Current: 19.83

-45.25
19.83
Revenue Growth (%) -3.00
RAD's Revenue Growth (%) is ranked higher than
57% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. RAD: -3.00 )
RAD' s 10-Year Revenue Growth (%) Range
Min: -16   Max: 15.1
Current: -3

-16
15.1
EBITDA Growth (%) 24.50
RAD's EBITDA Growth (%) is ranked higher than
95% of the 379 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. RAD: 24.50 )
RAD' s 10-Year EBITDA Growth (%) Range
Min: -15.3   Max: 30.5
Current: 24.5

-15.3
30.5
» RAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

RAD Guru Trades in Q2 2013

Pioneer Investments 46,623 sh (New)
Paul Tudor Jones 250,200 sh (New)
John Keeley 160,000 sh (New)
David Einhorn 20,200,000 sh (New)
Jim Simons 8,082,600 sh (+290.33%)
Tom Russo Sold Out
Ray Dalio Sold Out
Larry Robbins Sold Out
Joel Greenblatt 2,136,784 sh (-6.75%)
Steven Cohen 1,765,599 sh (-48.84%)
» More
Q3 2013

RAD Guru Trades in Q3 2013

Jeremy Grantham 141,338 sh (New)
Ken Fisher 14,510 sh (New)
Ray Dalio 96,000 sh (New)
Louis Moore Bacon 180,000 sh (New)
Paul Tudor Jones 1,620,500 sh (+547.68%)
Steven Cohen 4,270,739 sh (+141.89%)
John Keeley Sold Out
Pioneer Investments Sold Out
Joel Greenblatt 1,959,474 sh (-8.3%)
David Einhorn 16,160,000 sh (-20%)
Jim Simons 4,211,600 sh (-47.89%)
» More
Q4 2013

RAD Guru Trades in Q4 2013

Pioneer Investments 23,609 sh (New)
John Burbank 31,165 sh (New)
John Hussman 1,200,000 sh (New)
Ray Dalio 132,400 sh (+37.92%)
Steven Cohen 4,772,979 sh (+11.76%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Jeremy Grantham 140,092 sh (-0.88%)
Ken Fisher 11,500 sh (-20.74%)
David Einhorn 12,120,000 sh (-25%)
Joel Greenblatt 977,915 sh (-50.09%)
Paul Tudor Jones 91,000 sh (-94.38%)
» More
Q1 2014

RAD Guru Trades in Q1 2014

Jim Simons 1,593,000 sh (New)
George Soros 2,043,700 sh (New)
Paul Tudor Jones 2,104,420 sh (+2212.55%)
Ray Dalio 1,085,900 sh (+720.17%)
Ken Fisher 12,100 sh (+5.22%)
Jeremy Grantham Sold Out
Pioneer Investments Sold Out
John Burbank 26,509 sh (-14.94%)
John Hussman 1,000,000 sh (-16.67%)
David Einhorn 5,511,246 sh (-54.53%)
Steven Cohen 1,126,005 sh (-76.41%)
Joel Greenblatt 158,445 sh (-83.8%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 New Buy0.13%$5.04 - $6.92 $ 7.3221%2043700
Joel Greenblatt 2014-03-31 Reduce -83.8%0.1%$5.04 - $6.92 $ 7.3221%158445
Ray Dalio 2014-03-31 Add 720.17%0.05%$5.04 - $6.92 $ 7.3221%1085900
John Hussman 2013-12-31 New Buy0.43%$4.83 - $6.11 $ 7.3237%1200000
Joel Greenblatt 2013-12-31 Reduce -50.09%0.15%$4.83 - $6.11 $ 7.3237%977915
John Burbank 2013-12-31 New Buy0.01%$4.83 - $6.11 $ 7.3237%31165
Ray Dalio 2013-12-31 Add 37.92%$4.83 - $6.11 $ 7.3237%132400
John Keeley 2013-09-30 Sold Out 0.01%$2.74 - $4.94 $ 7.32115%0
Ray Dalio 2013-09-30 New Buy$2.74 - $4.94 $ 7.32115%96000
Ray Dalio 2013-06-30 Sold Out 0.02%$1.71 - $3.15 $ 7.32180%0
John Keeley 2013-06-30 New Buy0.01%$1.71 - $3.15 $ 7.32180%160000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Rite Aid Corp

Weekly Insider Sells Highlight: RAD, KOS, SNDK, AFOP
According to GuruFocus Insider Data, the largest insider sells during the past week were: Rite Aid Corp., Kosmos Energy Ltd., SanDisk Corp., Crown Holdings Inc. and Alliance Fiber Optic Products Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 56.20
RAD's P/E(ttm) is ranked higher than
58% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.80 vs. RAD: 56.20 )
RAD' s 10-Year P/E(ttm) Range
Min: 3.17   Max: 6590
Current: 56.2

3.17
6590
P/S 0.30
RAD's P/S is ranked higher than
79% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. RAD: 0.30 )
RAD' s 10-Year P/S Range
Min: 0.01   Max: 0.32
Current: 0.3

0.01
0.32
PFCF 23.50
RAD's PFCF is ranked higher than
81% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 56.31 vs. RAD: 23.50 )
RAD' s 10-Year PFCF Range
Min: 1.88   Max: 80.83
Current: 23.5

1.88
80.83
EV-to-EBIT 17.90
RAD's EV-to-EBIT is ranked higher than
67% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.42 vs. RAD: 17.90 )
RAD' s 10-Year EV-to-EBIT Range
Min: 9.6   Max: 618
Current: 17.9

9.6
618
PEG 2.70
RAD's PEG is ranked higher than
83% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.35 vs. RAD: 2.70 )
RAD' s 10-Year PEG Range
Min: 2.7   Max: 13.74
Current: 2.7

2.7
13.74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.80
RAD's Price/Median PS Value is ranked lower than
52% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.12 vs. RAD: 2.80 )
RAD' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 9.14
Current: 2.8

0.09
9.14
Earnings Yield (Greenblatt) 5.60
RAD's Earnings Yield (Greenblatt) is ranked higher than
62% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.80 vs. RAD: 5.60 )
RAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10.4
Current: 5.6

0.2
10.4
Forward Rate of Return (Yacktman) 0.92
RAD's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 332 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.13 vs. RAD: 0.92 )
RAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -78.3   Max: 35.3
Current: 0.92

-78.3
35.3

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:RTA.Germany
Rite Aid Corporation, a Delaware corporation was incorporated in 1968. It operates a retail drugstore chain in the United States. It operates its drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,623 stores. The Company sells prescription drugs and an assortment of other merchandise, which it calls 'front end' products. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other convenience products. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a retailer of vitamin and mineral supplements. The retail drugstore industry is competitive. It competes with retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices. It must comply with numerous provisions regulating health and safety, equal employment opportunity, minimum wage and licensing for the sale of drugs, alcoholic beverages, tobacco and other products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide